NOACs demonstrated a reduction in the composite of stroke or systemic embolic events OR 0.85 (95% CI 0.75 to 0.98), a 52% reduction in intracranial haemorrhage OR 0.48 (95% CI 0.40 to 0.57) and a 14% reduction in mortality OR 0.86 (0.82 to 0.91). MAIN RESULTS: 12 studies were identified with a total study population of 77 011. SEARCH METHODS: Medline, EMBASE and grey literature search for all phase II and III randomised control trials.ĭATA COLLECTION/ANALYSIS: Two authors independently reviewed abstracts and performed data extraction of eligible full-text articles. OBJECTIVES: The objective of this review was to evaluate the efficacy and safety of the NOACs versus warfarin in patients with AF. Novel oral anticoagulants (NOACs) are increasingly used as an alternative. BACKGROUND: Warfarin has been the anticoagulant of choice for the prevention of ischaemic stroke in patients with atrial fibrillation (AF).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |